Experiments revealed that patients with low pretherapeutic Ang-2 serum levels receiving a bevacizumab-containing treatment were associated with a better response rate compared to patients with high pretherapeutic Ang-2 levels. Additionally to a reduced risk of death (>90%) patients with low pretherapeutic Ang-2 levels showed a significant increase in progression-free survival (up to five months).
Furthermore, Ang-2 expression levels were elevated in the stromal tissue of CRC patients compared to healthy controls.
Thus Ang-2 represents a candidate predictive biomarker for aniogenesis-targeted mCRC therapy with respect to anti-VEGF antibodies or fusion constructs. Additionally, based on the biological background it might have a role in the prediction of efficacy of Ang-2/Tie2 targeting compounds.
On behalf of the University of Cologne, PROvendis offers access to rights for commercial use as well as the opportunity for further co-development and evaluation.
The strong diagnostic potential of the predictive biomarker has been demonstrated in pretherapeutic blood samples from colorectal cancer patients vs. healthy controls. In case of interest, we are pleased to inform you about the current status of the patent.